Deborah A.R. Dillon, M.D.
Co-Author
This page shows the publications co-authored by Deborah Dillon and Nancy Lin.
Connection Strength
0.915
-
Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):1105-1118.
Score: 0.227
-
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
Score: 0.211
-
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. Oncologist. 2019 07; 24(7):e441-e449.
Score: 0.198
-
p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nat Commun. 2022 Mar 18; 13(1):1473.
Score: 0.062
-
Integrative multiomics-histopathology analysis for breast cancer classification. NPJ Breast Cancer. 2021 Nov 29; 7(1):147.
Score: 0.061
-
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605.
Score: 0.056
-
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572.
Score: 0.054
-
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553.
Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.